Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV002596260 | SCV003503668 | uncertain significance | Retinoblastoma | 2022-07-15 | criteria provided, single submitter | clinical testing | In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Deleterious"; PolyPhen-2: "Benign"; Align-GVGD: "Class C25"). This variant has not been reported in the literature in individuals affected with RB1-related conditions. This variant is not present in population databases (gnomAD no frequency). This sequence change replaces isoleucine, which is neutral and non-polar, with threonine, which is neutral and polar, at codon 324 of the RB1 protein (p.Ile324Thr). |
Ambry Genetics | RCV004661579 | SCV005160598 | uncertain significance | Hereditary cancer-predisposing syndrome | 2024-06-21 | criteria provided, single submitter | clinical testing | The p.I324T variant (also known as c.971T>C), located in coding exon 10 of the RB1 gene, results from a T to C substitution at nucleotide position 971. The isoleucine at codon 324 is replaced by threonine, an amino acid with similar properties. This amino acid position is conserved. In addition, the in silico prediction for this alteration is inconclusive. Based on the available evidence, the clinical significance of this variant remains unclear. |